Cargando…
Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210198/ https://www.ncbi.nlm.nih.gov/pubmed/32395561 http://dx.doi.org/10.21037/atm.2020.01.65 |
| _version_ | 1783531233365458944 |
|---|---|
| author | Isaacs, James Clarke, Jeffrey Ready, Neal |
| author_facet | Isaacs, James Clarke, Jeffrey Ready, Neal |
| author_sort | Isaacs, James |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7210198 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72101982020-05-11 Keynote 42: Pembrolizumab, PD-L1, and where to draw the line Isaacs, James Clarke, Jeffrey Ready, Neal Ann Transl Med Editorial Commentary AME Publishing Company 2020-04 /pmc/articles/PMC7210198/ /pubmed/32395561 http://dx.doi.org/10.21037/atm.2020.01.65 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Isaacs, James Clarke, Jeffrey Ready, Neal Keynote 42: Pembrolizumab, PD-L1, and where to draw the line |
| title | Keynote 42: Pembrolizumab, PD-L1, and where to draw the line |
| title_full | Keynote 42: Pembrolizumab, PD-L1, and where to draw the line |
| title_fullStr | Keynote 42: Pembrolizumab, PD-L1, and where to draw the line |
| title_full_unstemmed | Keynote 42: Pembrolizumab, PD-L1, and where to draw the line |
| title_short | Keynote 42: Pembrolizumab, PD-L1, and where to draw the line |
| title_sort | keynote 42: pembrolizumab, pd-l1, and where to draw the line |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210198/ https://www.ncbi.nlm.nih.gov/pubmed/32395561 http://dx.doi.org/10.21037/atm.2020.01.65 |
| work_keys_str_mv | AT isaacsjames keynote42pembrolizumabpdl1andwheretodrawtheline AT clarkejeffrey keynote42pembrolizumabpdl1andwheretodrawtheline AT readyneal keynote42pembrolizumabpdl1andwheretodrawtheline |